Market Place
Sourcing Support
Melinta Announces IDWeek 2024 Presentations On Product Portfolio
16 Oct 2024 //
BUSINESSWIRE
Melinta Therapeutics Appoints Chief Technology Officer
05 Sep 2024 //
CONTRACT PHARMA
Melinta Therapeutics Appoints Sunitha as Chief Technology Officer
05 Sep 2024 //
BUSINESSWIRE
Melinta Therapeutics Appoints Fabrizio Tondolo As VP Of Medical Affairs
06 Aug 2024 //
BUSINESSWIRE
Melinta Rezafungin Candida Data: Restore Outcomes, Breakpoints Published
23 May 2024 //
BUSINESSWIRE
Venatorx and Melinta Provide Update on Status of NDA for Cefepime-Taniborbactam
23 Feb 2024 //
BUSINESSWIRE
Melinta & Cidara Announce Publication of Pooled Data from Phase 3 of REZZAYO
05 Dec 2023 //
BUSINESSWIRE
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement
09 Nov 2023 //
BUSINESSWIRE
Melinta Announces Presentations of Data on Infectious Disease Portfolio
11 Oct 2023 //
BUSINESSWIRE
Melinta Announces Expanded Reimbursement and Access for REZZAYO
02 Oct 2023 //
BUSINESSWIRE
Melinta Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
31 Jul 2023 //
BUSINESSWIRE
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics
10 Jul 2023 //
BUSINESSWIRE
Melinta secures $142M BARDA deal to target pediatric and `biothreat` indications
10 Jul 2023 //
ENDPTS
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement
15 May 2023 //
BUSINESSWIRE
FDA panel recommends rezafungin as new Candida treatment
26 Jan 2023 //
BUSINESSWIRE
Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event
30 Nov 2022 //
BUSINESSWIRE
Melinta Announces Presentation of New Data on Infectious Disease Portfolio
18 Oct 2022 //
BUSINESSWIRE
Melinta pays Cidara $30M for antifungal pending FDA review
27 Jul 2022 //
FIERCEBIOTECH
Melinta and Cidara Announce Licensing Agreement to Commercialize Rezafungin
27 Jul 2022 //
BUSINESSWIRE
Melinta Tx Acquires U.S. Rights to TOPROL-XL from New American Therapeutics
06 Apr 2022 //
BUSINESSWIRE
Melinta Therapeutics Appoints Peter Piliero as Vice President of Medical Affairs
14 Mar 2022 //
BUSINESSWIRE
Christine Ann Miller Elected to Board of Directors of Iveric Bio
06 Jan 2022 //
BUSINESSWIRE
Melinta Announces Two Key Milestones for KIMYRSA
20 Sep 2021 //
BUSINESSWIRE
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)
07 Jul 2021 //
BUSINESSWIRE
Melinta Therapeutics Announces Appointment of Susan Blum as CFO
29 Jun 2021 //
BUSINESSWIRE
Melinta Therapeutics Announces Appointment of Susan Blum as CFO
29 Jun 2021 //
BUSINESSWIRE
Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement
29 Apr 2021 //
BUSINESSWIRE
Melinta nabs FDA nod for more convenient rework of antibiotic Orbactiv
16 Mar 2021 //
ENDPTS
Melinta Therapeutics Announces FDA Approval of KIMYRSA™
15 Mar 2021 //
BUSINESSWIRE
Melinta won FDA approval for skin infection fighter Kimyrsa
15 Mar 2021 //
FIERCEPHARMA
Melinta Therapeutics Appoints CEO
03 Aug 2020 //
CONTRACTPHARM
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offe
24 Jun 2020 //
GLOBENEWSWIRE
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
04 Jun 2020 //
BUSINESSWIRE
Restructured Melinta now wants to buy fellow antibiotic maker Tetraphase
23 May 2020 //
ENDPTS
Nobody but Deerfield wants Melinta; Novartis finds a new drug discovery partner
05 Mar 2020 //
ENDPTS
Melinta seeks buyout bids to secure escape from bankruptcy
14 Feb 2020 //
FIERCE BIOTECH
Novo Holdings tweaks fund to take antibiotics deeper into the clinic
06 Jan 2020 //
FIERCE BIOTECH
Melinta files for bankruptcy in another dark day for antibiotics
03 Jan 2020 //
FIERCE BIOTECH
Melinta Therapeutics stock slides after company files for chapter 11 bankruptcy protection
30 Dec 2019 //
MARKET WATCH
Melinta Therapeutics Announces Restructuring Support Agreement
27 Dec 2019 //
GLOBE NEWSWIRE
Melinta CEO Johnson exits amid ‘changing circumstances’
10 Aug 2019 //
FIERCE BIOTECH
Hikma establishes partnership with Melinta in MENA
28 Feb 2019 //
BIOSPACE
Melinta Publication Highlights Baxdela Activity Against Fluoroquinolone
25 Jun 2018 //
PRESS RELEASE
Melinta Therapeutics Announces Closing of Underwritten Public Offering
29 May 2018 //
PRESS RELEASE
Melinta Partner, Menarini Group, Submits MAA for Delafloxacin in Europe
13 May 2018 //
PRESS RELEASE
Melinta Therapeutics Launches New Antibiotic Stewardship Program
08 May 2018 //
PRESS RELEASE
Intercept Appoints Nancy Miller-Rich to Its Board of Directors
24 Apr 2018 //
PRESS RELEASE
Melinta Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE
23 Apr 2018 //
PRESS RELEASE
Melinta Presents Results from VABOMERE TANGO II Trial at ECCMID 2018
23 Apr 2018 //
PRESS RELEASE
Melinta Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID
21 Apr 2018 //
PRESS RELEASE
Melinta to Highlight Commitment to Antibiotics and Product Portfolio
08 Mar 2018 //
PRESS RELEASE
Melinta Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™
27 Feb 2018 //
PRESS RELEASE
Melinta Commercial Partner Eurofarma Submit MAA for Delafloxacin in Argentina
20 Feb 2018 //
PRESS RELEASE
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the US
29 Jan 2018 //
PRESS RELEASE
Melinta Completes Acquisition of The Medicines Company’s
08 Jan 2018 //
PRESS RELEASE
Melinta Announces Successful Completion of Merger
06 Nov 2017 //
PRESS RELEASE
Melinta Provides for Distribution of Delafloxacin to 19 Countries
26 Sep 2017 //
PRESS RELEASE
Melinta Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials
25 Sep 2017 //
PRESS RELEASE
